, Tracking Stock Market Picks
Enter Symbol:
Ariad Pharmaceuticals, Inc. (ARIA) [hlAlert]

up 75.81 %

Ariad Pharmaceuticals, Inc. (ARIA) rated Buy with price target $35 by Brean Murray

Posted on: Monday,  Oct 1, 2012  9:25 AM ET by Brean Murray

Brean Murray rated Buy Ariad Pharmaceuticals, Inc. (NASDAQ: ARIA) on 10/01/2012. Previously Brean Murray rated Buy Ariad Pharmaceuticals, Inc. (NASDAQ: ARIA) on
05/05/2010., when the stock price was $3.97. Since then, Ariad Pharmaceuticals, Inc. has gained 75.82% as of 01/19/2016's recent price of $6.98.
If you would have followed the previous Brean Murray's recommendation on ARIA, you would have gained 75.81% of your investment in 2085 days.

Ariad Pharmaceuticals is engaged in the discovery and development of novel pharmaceuticals based on intracellular signaling technology. The Company has established highly integrated capabilities in functional genomics, molecular cell biology, structure based drug design, combinatorial chemistry and pharmacology. The company is developing small-molecule drugs that block signal transduction pathways in cells responsible for osteoporosis, and immune and inflammatory diseases.

Our equity research department is focused on fundamental analysis across the universe of over 200 small/mid cap stocks in our five target sectors. We are committed to providing proprietary action-oriented research to our institutional clients. Small cap growth focus. Our primary area of concentration is growth stocks with market capitalization of $200 million to $5 billion. Global perspective. We are covering U.S. listed stocks for companies domiciled in the U.S., China, Europe and Latin America, with our biggest concentration in the US and China. We were one of the first banks to aggressively expand our research to China and we believe we created one of the premier research franchises in small cap, U.S. listed Chinese companies to complement our strong domestic coverage. Disciplined stock selection. Our research analysts are focused on performing extensive bottoms up due diligence on companies under our coverage by leveraging their industry and management contacts. By combining our bottoms up work with our sector views we seek to generate a consistent flow of high conviction ideas for our clients. Diversified coverage. Our areas of expertise include technology, consumer, healthcare, resources and China small cap. We provide our clients with company-specific as well as sector-specific research across our target sectors.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
10/1/2012 9:25 AM Buy
24.98 35.00
as of 12/31/2012
1 Week down  -5.84 %
1 Month down  -14.22 %
3 Months down  -20.77 %
1 YTD up  56.57 %
Previous Recommendations
Date/Time (ET)SymbolRatingTermPrice (*)Target
8/2/2011 11:25 AM Buy
11.61 15.00
5/25/2011 8:25 AM Buy
8.31 11.00
1/19/2011 8:25 AM Buy
6.88 9.00
5/5/2010 2:25 PM Buy
3.97 5.00
10/8/2009 8:25 AM Hold

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy